We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novavax plans to have enough COVID-19 vaccine manufacturing capacity to meet U.S. demand at a minimum, but the Maryland-based vaccine developer is also looking to be able to supply billions of doses next year, the company’s CEO said. Read More
Moderna said that it might not be the first company to make the inventions claimed on patent applications for its COVID-19 vaccine mRNA-1273, and that the company may have to seek patent licenses to market the vaccine. Read More
Genentech has set a maximum yearly price of $340,000 for its recently approved spinal muscular atrophy drug Evrysdi (risdiplam), making the medicine notably less expensive than the other two SMA treatments on the market. Read More
The U.S. government’s $765 million loan to Eastman Kodak for a generic drug ingredient manufacturing facility aimed at reducing U.S. dependence on imports is on hold as federal investigators look into allegations of wrongdoing at the company. Read More
The Trump administration has said that the Department of Defense (DOD) will take the lead in distributing the COVID-19 vaccines secured under Operation Warp Speed, but some lawmakers are concerned that the administration has not yet released details of how that will be done. Read More
The Serum Institute of India has partnered with the Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance to manufacture 100 million doses of COVID-19 vaccines for low- and middle- income countries. Read More
Maryland-based Novavax has teamed up with Takeda Pharmaceutical Co. to commercialize Novavax’s COVID-19 vaccine candidate NVX-CoV2373 in Japan. Read More
Gilead Sciences said it should be able to meet international demand for remdesivir in October, thanks to improvements in its own processes and an expanded manufacturing network. Read More